The University of Southampton
University of Southampton Institutional Repository

Occurrence of psychosis and bipolar disorder in individuals with ADHD treated with stimulants: systematic review and meta-analysis

Occurrence of psychosis and bipolar disorder in individuals with ADHD treated with stimulants: systematic review and meta-analysis
Occurrence of psychosis and bipolar disorder in individuals with ADHD treated with stimulants: systematic review and meta-analysis
Importance: individuals with attention-deficit/hyperactivity disorder (ADHD) may present with psychosis or bipolar disorder (BD) following treatment with stimulants. The extent to which this occurs is currently unclear.

Objective: to meta-analytically quantify the occurrence of psychosis or BD after exposure to stimulants in individuals with ADHD and assess possible moderating factors.

Data sources: PubMed, Web of Science, Ovid/PsycINFO, and Cochrane Central Register of Reviews were searched from inception until October 1, 2024, without language restrictions.

Study selection: studies of any design with DSM or International Classification of Diseases–defined ADHD populations exposed to stimulants, where psychosis or BD outcomes were evaluated.

Data extraction and synthesis: PRISMA Preferred Reporting Items for Systematic Reviews and Meta-analyses and MOOSE Meta-analysis of Observational Studies in Epidemiology guidelines were followed, the protocol was registered, and the Newcastle-Ottawa scale and Cochrane risk of bias-2 tool were used for quality appraisal. Random-effects meta-analysis, subgroup analyses, and meta-regressions were conducted.

Main outcomes and measures : for the proportion of individuals developing psychotic symptoms, psychotic disorders, and BD, effect sizes are reported as percentages with 95% CIs. For the comparison between amphetamines and methylphenidate, effect sizes are presented as odds ratios with 95% CIs.

Results: sixteen studies (N = 391 043; mean [range] age, 12.6 [8.5-31.1] years; 288 199 [73.7%] male) were eligible. Among individuals with ADHD prescribed stimulants, 2.76% (95% CI, 0.73-9.88; k = 10; n = 237 035), 2.29% (95% CI, 1.52-3.40; k = 4; n = 91 437), and 3.72% (95% CI, 0.77-16.05; k = 4; n = 92 945) developed psychotic symptoms, a psychotic disorder, and BD, respectively. Heterogeneity across the studies was significant (I2 > 95%). Psychosis occurrence risk was significantly higher in individuals exposed to amphetamines than to methylphenidate (odds ratio [OR], 1.57, 95% CI, 1.15-2.16; k = 3, n = 231 325). Subgroup analyses showed significantly higher prevalence of psychotic symptoms in studies from North America and in those with longer follow-up periods. Increased psychosis occurrence was associated with a higher proportion of female participants, smaller sample sizes, and higher dose of stimulants.

Conclusions and relevance : this systematic review and meta-analysis found a nonnegligible occurrence of psychotic symptoms, psychotic disorders, or BD in individuals with ADHD treated with stimulants. Amphetamines were associated with higher occurrence compared to methylphenidate. The included studies cannot establish causality, highlighting the need for further research, including randomized clinical trials and mirror-image studies comparing individuals exposed and not exposed to stimulants. Nonetheless, clinicians should inform patients about the increased occurrence of psychosis or BD when discussing stimulant pharmacotherapy and systematically monitor for these conditions throughout treatment.
2168-6238
de Pablo, Gonzalo Salazar
12231d1e-94a6-495b-a5ff-2b4b99cbd37e
Aymerich, Claudia
c8cc318c-4c05-4d39-9d68-d881fa90710d
Chart-Pascual, Juan Pablo
6fc06063-e7a4-4841-9c13-6dee0684294d
Solmi, Marco
2022a2e4-774d-4811-b1db-b6dbfedbd10d
Torres-Cortes, Javier
762ccc0e-8e70-4da6-a291-68fc5c8f39bb
Abdelhafez, Nessma
7f68e9e5-ebcf-4970-a788-7d8cee436c90
Catalan, Ana
50bd5b40-15a0-48cc-8f9a-f3661ae133b5
Corbeil, Olivier
c0a17c2a-6264-4988-b804-96fdae0c2813
Adamo, Nicoletta
9732c74f-8f27-429c-8031-155fe9cbdc9d
Shaw, Philip
1625bc48-25a9-4521-89e1-f06b3564cbaf
Fusar-Poli, Paolo
62c59ab3-36bc-446b-9672-5565fdc76cf5
Cortese, Samuele
53d4bf2c-4e0e-4c77-9385-218350560fdb
de Pablo, Gonzalo Salazar
12231d1e-94a6-495b-a5ff-2b4b99cbd37e
Aymerich, Claudia
c8cc318c-4c05-4d39-9d68-d881fa90710d
Chart-Pascual, Juan Pablo
6fc06063-e7a4-4841-9c13-6dee0684294d
Solmi, Marco
2022a2e4-774d-4811-b1db-b6dbfedbd10d
Torres-Cortes, Javier
762ccc0e-8e70-4da6-a291-68fc5c8f39bb
Abdelhafez, Nessma
7f68e9e5-ebcf-4970-a788-7d8cee436c90
Catalan, Ana
50bd5b40-15a0-48cc-8f9a-f3661ae133b5
Corbeil, Olivier
c0a17c2a-6264-4988-b804-96fdae0c2813
Adamo, Nicoletta
9732c74f-8f27-429c-8031-155fe9cbdc9d
Shaw, Philip
1625bc48-25a9-4521-89e1-f06b3564cbaf
Fusar-Poli, Paolo
62c59ab3-36bc-446b-9672-5565fdc76cf5
Cortese, Samuele
53d4bf2c-4e0e-4c77-9385-218350560fdb

de Pablo, Gonzalo Salazar, Aymerich, Claudia, Chart-Pascual, Juan Pablo, Solmi, Marco, Torres-Cortes, Javier, Abdelhafez, Nessma, Catalan, Ana, Corbeil, Olivier, Adamo, Nicoletta, Shaw, Philip, Fusar-Poli, Paolo and Cortese, Samuele (2025) Occurrence of psychosis and bipolar disorder in individuals with ADHD treated with stimulants: systematic review and meta-analysis. JAMA Psychiatry. (doi:10.1001/jamapsychiatry.2025.2311).

Record type: Article

Abstract

Importance: individuals with attention-deficit/hyperactivity disorder (ADHD) may present with psychosis or bipolar disorder (BD) following treatment with stimulants. The extent to which this occurs is currently unclear.

Objective: to meta-analytically quantify the occurrence of psychosis or BD after exposure to stimulants in individuals with ADHD and assess possible moderating factors.

Data sources: PubMed, Web of Science, Ovid/PsycINFO, and Cochrane Central Register of Reviews were searched from inception until October 1, 2024, without language restrictions.

Study selection: studies of any design with DSM or International Classification of Diseases–defined ADHD populations exposed to stimulants, where psychosis or BD outcomes were evaluated.

Data extraction and synthesis: PRISMA Preferred Reporting Items for Systematic Reviews and Meta-analyses and MOOSE Meta-analysis of Observational Studies in Epidemiology guidelines were followed, the protocol was registered, and the Newcastle-Ottawa scale and Cochrane risk of bias-2 tool were used for quality appraisal. Random-effects meta-analysis, subgroup analyses, and meta-regressions were conducted.

Main outcomes and measures : for the proportion of individuals developing psychotic symptoms, psychotic disorders, and BD, effect sizes are reported as percentages with 95% CIs. For the comparison between amphetamines and methylphenidate, effect sizes are presented as odds ratios with 95% CIs.

Results: sixteen studies (N = 391 043; mean [range] age, 12.6 [8.5-31.1] years; 288 199 [73.7%] male) were eligible. Among individuals with ADHD prescribed stimulants, 2.76% (95% CI, 0.73-9.88; k = 10; n = 237 035), 2.29% (95% CI, 1.52-3.40; k = 4; n = 91 437), and 3.72% (95% CI, 0.77-16.05; k = 4; n = 92 945) developed psychotic symptoms, a psychotic disorder, and BD, respectively. Heterogeneity across the studies was significant (I2 > 95%). Psychosis occurrence risk was significantly higher in individuals exposed to amphetamines than to methylphenidate (odds ratio [OR], 1.57, 95% CI, 1.15-2.16; k = 3, n = 231 325). Subgroup analyses showed significantly higher prevalence of psychotic symptoms in studies from North America and in those with longer follow-up periods. Increased psychosis occurrence was associated with a higher proportion of female participants, smaller sample sizes, and higher dose of stimulants.

Conclusions and relevance : this systematic review and meta-analysis found a nonnegligible occurrence of psychotic symptoms, psychotic disorders, or BD in individuals with ADHD treated with stimulants. Amphetamines were associated with higher occurrence compared to methylphenidate. The included studies cannot establish causality, highlighting the need for further research, including randomized clinical trials and mirror-image studies comparing individuals exposed and not exposed to stimulants. Nonetheless, clinicians should inform patients about the increased occurrence of psychosis or BD when discussing stimulant pharmacotherapy and systematically monitor for these conditions throughout treatment.

Text
Salazar de Pablo_et_al_JAMA_Psychiatry_paper3 - Accepted Manuscript
Download (308kB)

More information

Accepted/In Press date: 11 July 2025
e-pub ahead of print date: 3 September 2025

Identifiers

Local EPrints ID: 504907
URI: http://eprints.soton.ac.uk/id/eprint/504907
ISSN: 2168-6238
PURE UUID: cbe5cfc8-fb1f-4766-8b2d-4957dcd53b97
ORCID for Samuele Cortese: ORCID iD orcid.org/0000-0001-5877-8075

Catalogue record

Date deposited: 22 Sep 2025 16:42
Last modified: 23 Sep 2025 01:51

Export record

Altmetrics

Contributors

Author: Gonzalo Salazar de Pablo
Author: Claudia Aymerich
Author: Juan Pablo Chart-Pascual
Author: Marco Solmi
Author: Javier Torres-Cortes
Author: Nessma Abdelhafez
Author: Ana Catalan
Author: Olivier Corbeil
Author: Nicoletta Adamo
Author: Philip Shaw
Author: Paolo Fusar-Poli
Author: Samuele Cortese ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×